All investment articles
-
ArticleGaelic Labs: Pharma is increasingly focused on supply chain security
General Manager Brian Morrissey discusses his company’s acquisition of fellow Beta-Lactam manufacturer Athlone Laboratories and its implications for an evolving industry.
-
NewsEli Lilly doubles down on supply chain investment in Asia
Pharma giant to strengthen manufacturing capabilities in Japan and add capacity in China for its first oral GLP-1 therapy candidate, orforglipron.
-
NewsSanofi gains access to first-in-class JAK inhibitor through $1.5bn licensing deal
Oral small molecule therapy rovadicitnib from Sino Biopharmaceutical offers potential to advance the pharma company’s haematology portfolio.
-
NewsUCB signs $1.1bn to autoimmune collaboration with Chinese biotech Antengene
License agreement involves development of ATG-201, a B cell-depleting bispecific T-cell engager, supporting the biopharma company’s immunology pipeline.
-
NewsNovartis to site fifth radioligand therapy manufacturing facility in Texas
Investment to support production of radiopharmaceutical cancer therapies and forms part of Novartis’ planned $23 billion investment in its US capabilities.
-
NewsGSK acquires TGF-beta protein firm 35Pharma for nearly $1bn
Acquisition will help GSK scale its pipeline for respiratory, immunology and inflammatory diseases.
-
NewsAbbVie invests $380m in Illinois to expand US API manufacturing
Decision forms part of the pharma company’s plan to commit $100 billion to its R&D capabilities in the US over the next decade.
-
NewsGilead adds to cell therapy portfolio with $8bn acquisition of Arcellx
Deal builds on the companies’ 2022 collaboration over CAR T therapy anito-cel.
-
NewsLilly acquires CAR-T therapy biotech Orna Therapeutics for $2.4bn
Agreement with Orna Therapeutics includes potential best-in-class, immune-targeting in vivo CAR-T therapies.
-
NewsVetter Pharma outlines plans for new manufacturing site in Germany
The CDMO is also building a new US aseptic clinical production facility in Illinois as it expands its global footprint.
-
NewsGSK acquires food allergy firm Rapt Therapeutics for $2.2bn
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
-
News
Amgen acquires UK cancer biotech Dark Blue Therapeutics for $840m
Gains access to the company’s small molecule-targeted protein degraders to expand its oncology pipeline.
-
NewsSamsung gains first US manufacturing site through $280m GSK deal
The CDMO will acquire the pharma company’s Human Genome Sciences facility in Maryland.
-
NewsAlnylam invests $250m to boost RNAi manufacturing in the US
Will add its enzymatic ligation platform, now accepted on the FDA’s emerging technology programme, to its Norton, Massachusetts site.
-
NewsLilly to establish third new US manufacturing facility in Alabama
Announcement of Eli Lilly and Company's fourth new US manufacturing plant is expected within the next few weeks.
-
NewsPfizer boosts its obesity plans with $2bn GLP-1 YaoPharma deal
The move builds on its recent billion-dollar acquisition of the obesity-focused biopharma company Metsera.
-
ArticleA careful calibration: balancing small molecule needs and biologic innovation
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
-
NewsNovartis adjusts manufacturing strategy in Switzerland to secure competitiveness
Swiss pharma company to trim production of oral medicines and packaging in Stein, while boosting productivity in Schweizerhalle.
-
News
AstraZeneca furthers US manufacturing commitment with $2bn Maryland investment
The move is part of biopharma's $50 billion pledge to US medicines manufacturing and R&D.
-
NewsModerna strengthens US mRNA manufacturing capabilities with over $140m investment
The expansion places the pharma company’s full manufacturing loop in the US under one roof.